Cancer Immunology, Immunotherapy

Published by: Springer  

People

  1. Aghajanian
    Aghajanian
  2. Hensley
    Hensley
  3. Iasonos
    Iasonos
  4. Kahn
    Kahn
  5. Konner
    Konner
  6. Makker
    Makker
  7. O'Cearbhaill
    O'Cearbhaill
  8. Ragupathi
    Ragupathi
  9. Sabbatini
    Sabbatini
  10. Tew
    Tew

Groups

  1. Biostatistics Service (1)
  2. Department of Medicine (1)
  3. Epidemiology and Biostatistics (1)
  4. GDMT, Medicine (1)
  5. GME, Surgery (1)
  6. Graduate Medical Education (1)
  7. Gynecologic Medicine Service (1)
  8. Gynecology Disease Management Team (1)
  9. Hematologic Malignancies, Division of (1)
  10. Melanoma Disease Management Team (1)
Search Within
  1. "Graduate Medical Education"
Formats
  1. Journal Article (1)
Groups
  1. Biostatistics Service (1)
  2. Department of Medicine (1)
  3. Epidemiology and Biostatistics (1)
  4. GDMT, Medicine (1)
  5. GME, Surgery (1)
  6. Graduate Medical Education (1)

More Groups

People
  1. Alexia Iasonos (1)
  2. Carol Aghajanian (1)
  3. Govindaswami Ragupathi (1)
  4. Jason Konner (1)
  5. Martee Hensley (1)
  6. Paul Sabbatini (1)

More People

Years
  1. 2023 (1)
Publishers
  1. Springer (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination
    Journal Article

    Kahn, R. M.; Ragupathi, G.; Zhou, Q. C.; Iasonos, A.; Kravetz, S.; Hensley, M. L.; Konner, J. A.; Makker, V.; Tew, W. P.; Aghajanian, C.; more...
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save

    • Cancer Immunology, Immunotherapy – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Immunology and Immunotherapy 978-3-642-14136-2 Springer Verlag
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Unknown
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology Immunotherapy 03407004 Springer Verlag
    Cancer Immunology Immunotherapy 03407004 Unknown
    Cancer Immunology Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 2022, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 2018, Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 2019, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2022, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2023, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2023, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag Berlin Heidelberg
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag Berlin Heidelberg
    Cancer Immunology, Immunotherapy 03407004 The Author(s) 2024
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Unknown
    Cancer Immunology, Immunotherapy 03407004 Us Government